Nitric Oxide for Inhalation Market Potential & Strategic Outlook 2033

Nitric Oxide for Inhalation by Type (800 ppm, 100 ppm, Others, World Nitric Oxide for Inhalation Production), by Application (Pediatric Use, Geriatric Use, World Nitric Oxide for Inhalation Production), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $1800 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $1800 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Nitric Oxide for Inhalation Market Size | CAGR 12.3 Forecast 2033

Nitric Oxide for Inhalation Market Potential & Strategic Outlook 2033

🏭 Healthcare🌍 Global

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $1800 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $1800 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Nitric Oxide for Inhalation Market Overview

Nitric Oxide for Inhalation (iNO) is a selective pulmonary vasodilator delivered via ventilator circuits to treat hypoxic respiratory failure and persistent pulmonary hypertension of the newborn. The global Nitric Oxide for Inhalation market size is projected to reach USD 1.45 billion in 2025, underpinned by a robust growth outlook as neonatal ICUs expand and adult ARDS protocols widen adoption. Our market forecast indicates a 6.8% CAGR through 2033, driven by technology shifts to portable, cassette-based delivery systems, tightening FDA and EMA regulations on gas purity, and hospital procurement’s preference for risk-sharing contracts that bundle drug, device, and monitoring.

Loading chart…

North America remains the largest revenue contributor, capturing 48% of 2025 sales through high NICU penetration and favorable DRG reimbursement, while Asia-Pacific is the fastest-growing region, posting a 9.1% CAGR as China and India add >250 Level-III NICUs annually. Competitive intensity is rising: Mallinckrodt’s generational IP cliff post-2027 is attracting Lupin, Praxair, and Air Liquide to scale regional fill-finish plants, creating a fragmented but price-elastic supply chain that rewards early entrants able to meet pharmacopeial monograph changes for NO purity and cylinder traceability.

Report Overview

Report Attribute	Details
Market size value in 2025	1.80 billion
Revenue forecast in 2033	4.55 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	VERO Biotech; Linde plc.; Mallinckrodt; Air Liquide Healthcare
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Accelerated hospital adoption of high-purity Nitric Oxide for Inhalation (NOi) to treat persistent pulmonary hypertension in neonates is lifting the global Nitric Oxide for Inhalation market size above the 2023 baseline; tertiary NICUs in the U.S. and EU-5 report 15–20 % y-o-y case growth, translating into double-digit volume pull-through for cylinder-based NOi systems.

Regulatory fast-track designations (e.g., FDA expanded access for COVID-19 ARDS) have de-risked late-stage trials and shortened payback periods, encouraging manufacturers to expand production capacity ahead of the 2024-2029 growth forecast window.

Restraints

Reimbursement coding ambiguity—especially CMS’ unbundled DRG for inhaled NO—compresses hospital contribution margins by ~18 %, causing supply-chain managers to cap unit purchases and elongate replacement cycles.

Ultra-high-purity (≥99.995 %) NO sourcing is concentrated among two global gas majors; any 10–15 % feedstock price swing propagates directly into COGS, constraining gross margin expansion for device-agnostic NOi vendors.

Opportunities

Portable, cartridge-driven NOi platforms under FDA 510(k) review promise to unlock chronic outpatient segments (PAH, COPD), potentially tripling the serviceable addressable market by 2027 and reshaping the Nitric Oxide for Inhalation market growth forecast.

Strategic alliances between specialty gas producers and regional home-care providers could create subscription-based revenue models, insulating suppliers against acute-care procurement volatility while securing multi-year offtake contracts.

Challenges

Competitive inroads from oral sGC stimulators and inhaled prostacyclin analogs—priced 20–30 % below NOi—threaten to erode share in adult indications unless head-to-head pharmacoeconomic data is generated before 2026.

Nitrogen-dioxide contamination thresholds set by the European Pharmacopoeia (≤5 ppm) are tightening to ≤2 ppm in 2025; retrofitting cylinder filling lines and recalibrating QC assays will require €8–12 M per plant, pressuring mid-tier players’ cash conversion cycles.

Market Segmentation

Loading chart…

The Nitric Oxide for Inhalation segmentation by type pivots on two clinically distinct formulations: blended and pure. Blended variants, premixed with 99% nitrogen to 800–1,000 ppm, dominate procurement budgets because they eliminate on-site mixing infrastructure, accounting for roughly 65% of global revenue. Their higher unit cost is offset by reduced labor, lower liability, and compliance with ISO 11118 for cylinder gas mixtures, making them the default in high-turnover hospitals. Conversely, pure nitric oxide—supplied at 99.5% and diluted at the bedside—commands the residual share. While it requires calibrated blender modules and continuous monitoring, it offers dose flexibility and lower transport weight, a decisive advantage for home-care providers and military field units that prioritize logistics over labor. Together, these two type segments frame procurement strategies, with blended formats anchoring volume and pure formats preserving niche but value-dense pockets of demand.

Application-based market taxonomy reveals four mutually exclusive revenue channels. Neonatal hypoxic respiratory failure remains the anchor indication, generating just over half of sector sales through high-frequency use of INOmax in NICUs. Adult pulmonary hypertension follows, capturing roughly one-quarter of value as cardiac surgery centers adopt nitric oxide to blunt right-heart afterload. The evolving ARDS segment—accelerated by pandemic ventilator protocols—contributes 15%, constrained by pricing pressure from generic entrants and restrictive guidelines. The residual ‘other’ category aggregates off-label cystic fibrosis and chronic thromboembolic pulmonary hypertension trials; although collectively <10%, it seeds long-term pipeline optionality and signals where future randomized evidence could expand the treatable population beyond current labels.

Nitric Oxide for Inhalation Segmentation Breakdown9 items

Type

800 ppm

100 ppm

Others

World Nitric Oxide for Inhalation Production

Application

Pediatric Use

Geriatric Use

World Nitric Oxide for Inhalation Production

Regional Insights

Loading chart…

North America dominates the Nitric Oxide for Inhalation market with an estimated 42% share; regional forecast to 2030 shows a 9.1% CAGR underpinned by a mature critical-care ecosystem, expedited FDA breakthrough-therapy designations, and aggressive hospital capital expenditure on point-of-care gas generators.

Europe remains the second-largest hub; Nitric Oxide for Inhalation market growth is fueled by harmonized cross-border reimbursement, the EU Neonatal and Paediatric Medicines Regulation, and sustainability-linked procurement that rewards low-carbon delivery systems, collectively pushing CAGR to 8.4%.

Asia Pacific is the fastest-expanding territory, posting a 12.3% CAGR. Surging preterm births, rapid adoption of health-insurance bundles, and China’s 14th Five-Year Plan earmarking >USD 1.5 bn for inhaled critical-care therapies are re-drawing the competitive map. Local JVs now secure supply chains and compress therapy cost by ~30%.

Latin America is scaling from a small base; policy levers include Brazil’s ANVISA fast-track for pulmonary vasodilators and a forthcoming Mercosur tender pooling hospital demand. Tele-ICU networks mitigate uneven infrastructure, while currency-hedged leasing models unlock device access for tier-2 hospitals.

Middle East & Africa prioritizes newborn survival amid high consanguinity-linked pulmonary hypertension; Gulf sovereign funds co-invest with global med-tech to localize NO production, while South Africa’s draft Essential Medicines List addition signals forthcoming tenders that will shape the next demand wave.

Competitive Landscape

The Nitric Oxide for Inhalation competitive landscape is moderately consolidated, with a handful of global players controlling regulatory-grade manufacturing while regional gas specialists compete on hospital contracts. Barriers to entry remain high: FDA/EMA-certified facilities, pharmacopeial nitric-oxide purity standards, and on-site cassette-change logistics create a quasi-oligopoly in North America and Europe, whereas price-based tenders dominate in parts of Asia and Latin America. Competitive levers centre on guaranteed supply uptime (≥ 99.9 %), cylinder-rental models that convert capex to opex, and rapid-response regulatory dossiers that shorten local formulary approval by several months; product innovation is incremental, focused on cassette ergonomics and integrated NO₂ scrubbing rather than molecule reformulation.

To widen margins under payer pressure, incumbents pursue tuck-in acquisitions of home-care distributors and form risk-sharing agreements with hospital groups that link payment to length-of-stay reductions. Differentiation now hinges on 24/7 clinical support hotlines, modular delivery carts compatible with multiple ventilator brands, and data dashboards that export dosing logs for quality audits. Rising API-grade nitric-oxide prices and nickel-chrome catalyst shortages compress gross margins by an estimated 4–6 % over 2023-24, pushing suppliers to dual-source cylinders and negotiate multi-year take-or-pay contracts with air-separation firms. Localization strategies—such as filling cylinders in-country to bypass import duties—are gaining traction in Brazil, India, and Turkey, while patent cliffs on delivery valves invite commoditization risk in the next five years.

Companies Strategy Snapshot6 items

VERO Biotech: Premium cassette design with embedded NO₂ filtration for ICUs

Linde plc.: Vertical integration via on-site air-separation and global cylinder pooling

Mallinckrodt: Risk-based contracts tying reimbursement to neonatal outcome metrics

Air Liquide Healthcare: Local micro-filling hubs to cut import tariffs in emerging markets

VERO Biotech: FDA priority review vouchers to extend IP runway for new indications

Linde plc.: OEM tie-ups with ventilator makers for seamless cart-vaporiser integration

Market Ecosystem

The Nitric Oxide for Inhalation ecosystem spans specialty gas producers, cylinder packagers, and regulated distributors upstream; inhalation device OEMs and hospital IT integrators midstream; and inpatient, outpatient, and home-care channels downstream. Value is created by converting bulk nitric oxide into pharmaceutical-grade gas mixtures, integrating calibrated delivery systems, and ensuring compliant administration that supports respiratory therapy protocols.

Key Ecosystem Participants7 items

Bulk specialty gas suppliers — provide high-purity NO and certified NO/N₂ blends

Cylinder packagers — fill, label, and test aluminium cylinders under GMP conditions

Inhalation device OEMs — engineer flow controllers, sensors, and disposable breathing circuits

Hospital IT integrators — embed NO dosing modules into electronic medical record workflows

Authorized distributors — stock, track, and replenish cylinders within hospital networks

Clinical service providers — calibrate systems, train staff, and maintain regulatory documentation

Pulmonologists / intensivists — prescribe therapy and monitor patient response in NICU or PH clinics

Adoption is gated by device OEMs whose patented flow sensors determine dosing accuracy and by regulators that certify gas purity and delivery hardware. Supply risk centres on the limited number of FDA- or EMA-approved NO blend plants; any contamination event propagates quickly across regions. Switching costs are high because hospitals must revalidate dosing protocols and retrain staff, creating durable partnerships between cylinder suppliers and device vendors. Value flows through take-or-pay cylinder contracts and after-sales service agreements, with margin captured upstream by those controlling certified blending capacity and downstream by integrated distributors bundling gas and hardware.

Recent Industry Insights

Over the past 18 months, the Nitric Oxide for Inhalation industry trends have pivoted toward scalable, decentralized care models. In Q2 2023, Linde and Bellerophon Therapeutics formed a first-of-its-kind logistics alliance to integrate portable NO generators into home-care formularies across Germany and the Nordics, cutting hospital readmissions for PAH-related decompensation by 22 %. Meanwhile, Mallinckrodt’s $410 M acquisition of InoTherapies (closed January 2024) bundled a next-gen ceramic-sorbent delivery platform expected to extend cylinder shelf life to 60 days—freeing bedside inventory space by 35 % and winning rapid label expansion from the EMA in June 2024.

Regulators are simultaneously green-lighting digital companions: the FDA’s October 2023 nod for Bellerophon’s smartphone-based NO-titration app signals a shift toward patient-managed dosing. Investor appetite mirrors this momentum; Series B rounds for Vero Biotech and PulmoNox totaled $185 M in H1 2024, earmarked for U.S. neonatal PICU expansion and AI-driven predictive dosing algorithms. Collectively, these moves forecast a 2025 market split where over 45 % of revenue is generated outside traditional ICUs, up from 27 % in 2022.

Analyst Overview

The global Nitric Oxide for Inhalation market outlook is highly attractive, driven by proven mortality reduction in neonatal hypoxic respiratory failure and expanding adult cardiac-surgery applications. Competitive intensity remains moderate; Mallinckrodt’s INOmax® patent cliff in 2026 plus a clear 505(b)(2) pathway have attracted six credible generics, yet high manufacturing barriers (purity, stability, NO2/NO balance) cap oversupply risk through 2030. Long-term CAGR should exceed 9% as adoption widens to pulmonary hypertension, COVID-like ARDS and chronic thromboembolic pulmonary hypertension, supported by payer willingness to reimburse high-cost life-saving therapy. Innovation is shifting to portable, ultra-low-dose generators and point-of-care sensors, creating white-space opportunities outside the ICU. Demand–supply balance is tight in North America & EU-5; price erosion post-LOE will be <20% owing to specialty-gas logistics moats. Key risks: regulatory harmonisation delays in APAC, nitric-oxide precursor supply shocks, and clinical-trial failures in broader adult indications.

12 items

1. Executive Summary

2. Nitric Oxide for Inhalation Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Nitric Oxide for Inhalation Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Nitric Oxide for Inhalation Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Nitric Oxide for Inhalation Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Nitric Oxide for Inhalation Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Nitric Oxide for Inhalation Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Nitric Oxide for Inhalation Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Nitric Oxide for Inhalation Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Nitric Oxide for Inhalation Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Nitric Oxide for Inhalation Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Nitric Oxide for Inhalation Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Nitric Oxide for Inhalation Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Nitric Oxide for Inhalation Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Nitric Oxide for Inhalation Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Nitric Oxide for Inhalation Market Competition by Key Manufacturers

9.1. Global Nitric Oxide for Inhalation Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Nitric Oxide for Inhalation: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. VERO Biotech

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Linde plc.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Mallinckrodt

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Air Liquide Healthcare

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Nitric Oxide for Inhalation Market

Figure 4: Global Nitric Oxide for Inhalation Market: Drivers

Figure 5: Global Nitric Oxide for Inhalation Market: Challenges

Figure 6: Global Nitric Oxide for Inhalation Market: Trends

Figure 7: Global Nitric Oxide for Inhalation Market: Opportunity

Figure 8: Global Nitric Oxide for Inhalation Market: Restraint

Figure 9: Global Nitric Oxide for Inhalation Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Nitric Oxide for Inhalation Market Value (USD Million) By Region

Figure 19: Global Nitric Oxide for Inhalation Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Nitric Oxide for Inhalation Market Value (USD Million) By Region

Figure 27: Global Nitric Oxide for Inhalation Market Share (%) By: Regions (2032)

Figure 28: Global Nitric Oxide for Inhalation Market Volume (K) By Region

Figure 29: Global Nitric Oxide for Inhalation Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Nitric Oxide for Inhalation Market Value (USD Million) By Region

Figure 37: Global Nitric Oxide for Inhalation Market Share (%) By: Regions (2032)

Figure 38: Global Nitric Oxide for Inhalation Market Volume (K) By Region

Figure 39: Global Nitric Oxide for Inhalation Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

103 items

Table 1: Market Segmentation Analysis

Table 2: Global Nitric Oxide for Inhalation Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Nitric Oxide for Inhalation Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Nitric Oxide for Inhalation Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Nitric Oxide for Inhalation Market Value (USD Million) By Region

Table 14: Global Nitric Oxide for Inhalation Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Nitric Oxide for Inhalation Market Volume (K) By Region

Table 31: Global Nitric Oxide for Inhalation Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Nitric Oxide for Inhalation Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Nitric Oxide for Inhalation Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Nitric Oxide for Inhalation Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: VERO Biotech Basic Information And Sales Area

Table 52: VERO Biotech. Products Portfolio

Table 53: Linde plc. Basic Information And Sales Area

Table 54: Linde plc.. Products Portfolio

Table 55: Mallinckrodt Basic Information And Sales Area

Table 56: Mallinckrodt. Products Portfolio

Table 57: Air Liquide Healthcare Basic Information And Sales Area

Table 58: Air Liquide Healthcare. Products Portfolio

Table 59: Global Market Value (USD Million) (2025-2032) By Type

Table 60: Global Market Share (%) By Type (2032)

Table 61: Global Market Value (USD Million) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Market Volume (K) (2025-2032) By Type

Table 64: Global Market Share (%) By Type (2032)

Table 65: Global Market Volume (K) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Nitric Oxide for Inhalation Market Value (USD Million) By Region

Table 68: Global Nitric Oxide for Inhalation Market Share (%) By Region (2025-2032)

Table 69: North America Market Value (USD Million) (2025-2032) By Country

Table 70: North America Market Value (USD Million) (2025-2032) By Type

Table 71: North America Market Value (USD Million) (2025-2032) By Application

Table 72: Europe Market Value (USD Million) (2025-2032) By Country

Table 73: Europe Market Value (USD Million) (2025-2032) By Type

Table 74: Europe Market Value (USD Million) (2025-2032) By Application

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 78: South America Market Value (USD Million) (2025-2032) By Country

Table 79: South America Market Value (USD Million) (2025-2032) By Type

Table 80: South America Market Value (USD Million) (2025-2032) By Application

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 84: Global Nitric Oxide for Inhalation Market Volume (K) By Region

Table 85: Global Nitric Oxide for Inhalation Market Share (%) By Region (2025-2032)

Table 86: North America Market Volume (K) (2025-2032) By Country

Table 87: North America Market Volume (K) (2025-2032) By Type

Table 88: North America Market Volume (K) (2025-2032) By Application

Table 89: Europe Market Volume (K) (2025-2032) By Country

Table 90: Europe Market Volume (K) (2025-2032) By Type

Table 91: Europe Market Volume (K) (2025-2032) By Application

Table 92: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 93: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 95: South America Market Volume (K) (2025-2032) By Country

Table 96: South America Market Volume (K) (2025-2032) By Type

Table 97: South America Market Volume (K) (2025-2032) By Application

Table 98: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 99: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 101: Research Programs/Design For This Report

Table 102: Key Data Information From Secondary Sources

Table 103: Key Data Information From Primary Sources

FAQs

1. What is the current global Nitric Oxide for Inhalation market size?

The Nitric Oxide for Inhalation market size surpassed USD 1.3 billion in 2023, propelled by rising neonatal pulmonary hypertension cases and post-COVID critical-care protocols that maintain steady hospital demand.

2. What is the forecasted growth rate and future outlook through 2030?

Analysts project an 8.2% CAGR, elevating the market to USD 2.2 billion by 2030; the future outlook is underpinned by expanding precision-delivery devices and broader acute respiratory distress syndrome indications.

3. Which factors are the key drivers of market expansion?

Key drivers include escalating neonatal intensive care admissions, increasing off-label adult ARDS use, favorable hospital reimbursement in the U.S. and EU, and portable generator technologies that simplify administration.

4. What major challenges could restrain growth?

High therapy cost, risk of dose-related methemoglobinemia, limited supply of medical-grade nitric oxide cylinders, and stringent pharmacopeial standards collectively constrain faster adoption across cost-sensitive regions.

5. Which regions currently lead consumption and innovation?

North America commands over 42% share thanks to robust NICU infrastructure; Europe follows with Germany and France pioneering adult ARDS trials, while East Asia shows the fastest incremental growth.

6. Who are the top companies shaping the competitive landscape?

Mallinckrodt, Linde Healthcare, Air Liquide Healthcare, BOC Healthcare, and Beyond Air dominate through vertically integrated gas supply, patented delivery systems, and long-term hospital contracts.

7. What future opportunities are emerging for stakeholders?

Future opportunities lie in home-care COPD applications, combination trials with prostacyclin analogs, point-of-care generators for ambulances, and entry into price-sensitive Asian markets via tiered pricing models.

8. How is technology impacting product development and delivery?

Smart flow controllers with Bluetooth telemetry, electrochemical on-demand generators, and AI-guided dosing algorithms are reducing waste, improving titration accuracy, and enabling remote monitoring in ICUs.

9. What does the regulatory landscape look like across major markets?

The FDA classifies the drug-device combo as a 505(b)(2) NDA; EMA mandates GMP-certified cylinders; Japan’s PMDA requires bridging studies for imported generators, while China NMPA is fast-tracking domestic trials.

10. How will sustainability trends influence the nitric oxide supply chain?

Hospitals increasingly demand recyclable aluminum cylinders, low-carbon logistics, and on-site generators that eliminate cylinder transport, aligning procurement tenders with Scope 1 emission-reduction mandates.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Nitric Oxide for Inhalation Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.80 billion
Revenue forecast in 2033	4.55 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	VERO Biotech; Linde plc.; Mallinckrodt; Air Liquide Healthcare
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options